Long-term results of intravesical therapy for superficial bladder cancer.
about
Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guérin strains that secrete cytokinesImmunotherapy in genitourinary malignancies.Update on the management of non-muscle invasive bladder cancer.Mycobacterium bovis BCG producing interleukin-18 increases antigen-specific gamma interferon production in mice.Update on intravesical agents for non-muscle-invasive bladder cancerIntravesical therapy for urothelial carcinoma of the urinary bladder: a critical review.Use of bacille Calmette-Guérin in superficial bladder cancer.Detection of bacillus Galmette-Guérin (Mycobacterium bovis BCG) DNA in urine and blood specimens after intravesical immunotherapy for bladder carcinoma.A novel method for monitoring Mycobacterium bovis BCG trafficking with recombinant BCG expressing green fluorescent protein.Proliferation markers and DNA content analysis in urinary bladder TaT1 urothelial cell carcinomas: identification of subgroups with low and high stage progression risks.Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes.Myobacterium bovis peri-prosthetic hip infection with successful prosthesis retention following intravesical BCG therapy for bladder carcinomaGermline prognostic markers for urinary bladder cancer: obstacles and opportunities.Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder.Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors.Comparison of 30 mg and 40 mg of mitomycin C intravesical instillation in Korean superficial bladder cancer patients: prospective, randomized studyIntravesical therapy for urothelial carcinoma of the bladder.Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity.Exploring the Therapeutic Efficacy of Glioma Vaccines Based on Allo- and Syngeneic Antigens and Distinct Immunological Costimulation Activators.Local immunostimulation induced by intravesical administration of autologous interferon-gamma-activated macrophages in patients with superficial bladder cancer.Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity.
P2860
Q33591159-9E28A714-9C85-4C60-86FB-32EC6C4B75C2Q33593800-765F0570-DE32-4C42-9819-DCA13FA8DBD1Q33613070-3A7B6924-69E9-4F26-9070-47661B5FF184Q34258548-F9B8E8CF-946D-4A8C-B4C6-A7B9CB641587Q34584575-643E88E9-8784-441A-A107-2AE1EE9731E9Q34751946-193AC708-2D30-4CC8-BE65-104DA5F2F6E1Q34788204-618B94E8-68D6-448C-929A-17B9FF36FE18Q35067132-4309C751-902F-4D29-85BE-74EC59A8D982Q35228328-C28F3FD4-DFA4-4C3C-B5AE-89E902CF025BQ35586813-FD9F3B55-ED15-4F31-9319-23862C43F19BQ35782803-17A4B5CA-D896-4706-AE15-A297C6577672Q36276438-81CA8456-4E04-4ECD-87BD-13E47C39D9F7Q37298808-0AC3788A-55C0-432B-9F89-611BA044B401Q37352975-F3E07937-2744-4CCD-9060-31BFD69307D4Q37403151-5F868606-99E6-47C4-86B9-73AEEEFDA074Q37447056-D1D81609-9A29-472A-BBF6-0D50B31C1ACAQ37911278-C7B36455-BF17-4481-AA2F-EAA3A6F42592Q40545635-8976EAB0-8019-4635-B056-D344855B98DCQ40847481-72A7A38E-01B2-4CE7-B1B1-67C007CB0401Q43904333-7B722A33-CA03-4011-B915-835252DE9383Q54792101-ED15A1C3-E989-4DD8-9631-10ABB1555616
P2860
Long-term results of intravesical therapy for superficial bladder cancer.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
Long-term results of intravesical therapy for superficial bladder cancer.
@ast
Long-term results of intravesical therapy for superficial bladder cancer.
@en
type
label
Long-term results of intravesical therapy for superficial bladder cancer.
@ast
Long-term results of intravesical therapy for superficial bladder cancer.
@en
prefLabel
Long-term results of intravesical therapy for superficial bladder cancer.
@ast
Long-term results of intravesical therapy for superficial bladder cancer.
@en
P1476
Long-term results of intravesical therapy for superficial bladder cancer.
@en
P2093
P304
P577
1992-08-01T00:00:00Z